Plain-English translation of NCT04707261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial investigates whether , a diabetes medication, can help people with heart failure by improving their blood counts and reducing the need for hospitalization. Researchers already know this medication helps the heart, but they want to understand if improving anemia (low red blood cell count) is one of the ways it works. You would receive either the medication or a placebo alongside your regular heart failure treatments.
Heart failure patients often develop anemia, which makes their condition worse and increases the risk of hospitalization and death. While this medication has already been shown to help heart failure, doctors want to understand whether it also helps by correcting low blood counts, which could explain some of its benefits.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill—either the medication or a placebo—along with your regular heart failure medications. You would visit the clinic at 3 months, 6 months, and 1 year to have blood tests and check-ups so doctors can track changes in your blood counts and how often you are hospitalized. The entire study lasts 1 year, and neither you nor your doctors will know whether you're receiving the medication or placebo until the study ends.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Xiangtan Central Hospital
Collaborators
Second Xiangya Hospital of Central South University, ZhuZhou Central Hospital
Enrollment target
~1,990 participants
Started
August 2021
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianping Zeng, Ph.D.
Xiangtan Central Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.